SNTI stock forecast, quote, news & analysis
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases... Show more
Why Senti Biosciences (SNTI) Stock Is Down -47% in the Last 30 Days
Key Takeaways
- Senti Biosciences (SNTI) shares fell roughly 47% over the last 30 days, sliding from about $0.31 to approximately $0.17 as a major restructuring transaction dominated the narrative.
- The decline followed the October 21, 2026 closing of a merger in which shareholders received no upfront cash, only contingent value rights (CVRs) tied to future milestones.
- The CVRs can pay out up to $60 million in total, contingent on regulatory and sales milestones for the lead candidate SENTI-202, with payments described as highly speculative.
- Dilutive share issuances, a Nasdaq minimum-bid deficiency notice, and a proposed reverse stock split added further downward pressure on the stock.
- The company has refocused on controllable genetic medicines, retaining early-stage programs in Rett syndrome and tumor-infiltrating lymphocytes (TILs).
- For additional detail, explore Senti Biosciences' Price Targets, Earnings, and Forecast pages.
- Discover how automated strategies approach this and other names by exploring Trending AI Robots.
Senti Biosciences (SNTI) Company Overview and Market Position
Senti Biosciences Holdings, Inc. is a clinical-stage biotechnology company built around synthetic biology and gene-circuit engineering. Its proprietary platform designs "logic-gated" cell therapies intended to selectively attack cancer cells while sparing healthy tissue. The company's lead candidate, SENTI-202, is an off-the-shelf CAR-NK cell therapy designed to target CD33 and FLT3 expressing blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The candidate has received Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the U.S. Food and Drug Administration.
Following a strategic transaction completed in late 2026, the company shifted its focus toward next-generation controllable genetic medicines powered by its Regulator Dial platform, retaining early-stage programs in Rett syndrome and tumor-infiltrating lymphocytes. Investors have historically followed the stock for its differentiated gene-circuit technology and the clinical progress of SENTI-202.
Senti Biosciences (SNTI) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Senti Biosciences shares declined approximately 47%, moving from a closing price near $0.31 to roughly $0.17. The move accelerated in mid-to-late October as the company's merger transaction reached completion, and the shares remain at depressed penny-stock levels.
Over the last quarter, the trend has been similarly negative, with the stock steadily eroding from levels around $0.38 in late August to the current range. The multi-month decline reflects a combination of structural changes to the company's ownership and pipeline, ongoing financial pressures, and reduced investor visibility into the future value of the business.
What Drove SNTI Stock Price in the Last 30 Days
The sharpest catalyst was the October 21, 2026 closing of a merger with ST NewCo Limited, formerly Celadon Partners SPV 35, under an agreement signed on July 14, 2026. Under the deal, shareholders received no cash at closing. Instead, each share carried one contingent value right, with payments tied to milestones for SENTI-202: up to $10 million upon acceptance of a Biologics License Application, $20 million upon FDA approval, and $30 million if cumulative worldwide net sales exceed $200 million. The maximum aggregate payout is $60 million, and the rights expire seven years after closing.
Because the CVRs are highly contingent and carry no voting or dividend rights, the market repriced the shares downward to reflect the uncertainty of any eventual payout. Additional dilution from a notes-for-equity exchange and a private share issuance, a Nasdaq minimum-bid deficiency notice issued in late August 2026, and a proposed reverse stock split also weighed on the stock. A board resignation in late October added to the perception of transition risk.
What Drove SNTI Stock Performance Over the Last Quarter
The quarterly decline reflects a broader strategic reset rather than a single-day event. In July 2026, the company announced plans to transfer its gene-circuit pipeline, including SENTI-202, to a newly formed private entity while refocusing the public company on controllable genetic medicines. This restructuring removed the most advanced clinical asset from the listed entity and replaced shareholder consideration with contingent rights of uncertain value.
Compounding the move, the company reported a shrinking cash position and a stockholders' equity deficit as of mid-2026, alongside disclosures of substantial doubt about its ability to continue operations without additional capital. These financial disclosures, combined with the proposed reverse split intended to restore Nasdaq listing compliance, contributed to sustained selling pressure throughout the period.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers across the market, but only the top-performing and most relevant strategies are surfaced in its curated Trending AI Robots section. These automated systems vary widely in strategy, timeframe, and performance metrics, giving traders a range of approaches to explore depending on their objectives and risk tolerance. The section is designed to help users identify bots that are currently demonstrating strong or notable performance, rather than presenting every available model. Investors interested in how quantitative, rule-based strategies handle volatile situations like Senti Biosciences' restructuring can review the section to see which automated approaches are generating attention.
SNTI Stock Forecast Drivers: What Investors Should Watch Next
Going forward, the most important factor is whether SENTI-202 achieves the regulatory and commercial milestones that would trigger CVR payouts, including BLA acceptance, FDA approval, and eventual sales thresholds. Because these outcomes are uncertain and years away, CVR value will remain highly speculative.
Investors should also monitor the company's efforts to restore Nasdaq listing compliance, including any reverse stock split, as well as its ability to secure financing for the retained Rett syndrome and TIL programs. The development of these earlier-stage assets, the company's cash runway, and any updates on its Regulator Dial platform will be key indicators of the public entity's long-term prospects. As always, these factors should be weighed carefully rather than treated as predictions of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SNTI in -12.12% downward trend, declining for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SNTI declined for three days, in 273 of 312 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNTI as a result. In 79 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Aroon Indicator for SNTI entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SNTI's RSI Oscillator exited the oversold zone, 36 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for SNTI just turned positive on November 11, 2026. Looking at past instances where SNTI's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
Following a +16.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNTI advanced for three days, in 194 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SNTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.465) is normal, around the industry mean (3.498). P/E Ratio (-0.095) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (166.667) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. SNTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology